Orladeyo FDA Approval History
Last updated by Judith Stewart, BPharm on Jan 27, 2021.
FDA Approved: Yes (First approved December 3, 2020)
Brand name: Orladeyo
Generic name: berotralstat
Dosage form: Capsules
Company: BioCryst Pharmaceuticals, Inc.
Treatment for: Hereditary Angioedema
Orladeyo (berotralstat) is a plasma kallikrein inhibitor indicated for prophylaxis to prevent attacks of hereditary angioedema (HAE) in adults and pediatric patients 12 years and older.
Development timeline for Orladeyo
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.